Peptide Formulations and Methods of Use

JP2023549126A5Pending Publication Date: 2024-11-12レアルタライフサイエンシズインコーポレイテッド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527357
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-09
Filing Date
2021-11-03
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Current therapies for dysregulated complement activation in autoimmune and inflammatory diseases are limited, particularly for common conditions, and there is a need for peptide-based inhibitors that can selectively modulate the classical and lectin pathways without affecting the alternative pathway, which is crucial for immune surveillance.

Method used

Development of lipid-based formulations of synthetic peptides, such as PA-I8Sar, which are designed to inhibit the classical and lectin pathways of the complement system by binding to C1q and MBL, while leaving the alternative pathway intact, using excipients like citric acid, ascorbic acid, and amino acids for intravenous administration.

Benefits of technology

The formulations effectively inhibit complement activation, providing therapeutic benefits for diseases mediated by dysregulated classical and lectin pathways, maintaining immune function by preserving the alternative pathway, and are suitable for various disease indications including autoimmune disorders and ischemia-reperfusion injuries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000033_0000
    Figure 00000033_0000
  • Figure 00000033_0001
    Figure 00000033_0001
  • Figure 00000033_0002
    Figure 00000033_0002
Patent Text Reader

Abstract

The present invention provides synthetic peptides. The present invention relates to modified 15 amino acid synthetic peptides from Polar Assortant (PA) peptide, a scrambled peptide derived from a human astrovirus protein. In some embodiments, the present invention relates to pharmaceutical formulations of the peptides, including lipid-based formulations and formulations suitable for intravenous administration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to Related Applications This application claims priority to U.S. Provisional Application No. 63 / 111,367, filed on November 9, 2020, the disclosure of which is hereby incorporated by reference in its entirety.

[0002] Sequence Listing This application is electronically filed in ASCII format and includes a sequence listing which is hereby incorporated by reference in its entirety. The ASCII copy was created on October 25, 2021, named 251110_000157_SL.txt, and is 1,169 bytes in size.

[0003] 1. Field of the Invention Aspects of the present invention generally relate to synthetic peptides for therapy and diagnosis and their use, and more specifically to pharmaceutical formulations of such peptides including lipid - based formulations and formulations suitable for intravenous administration.

Background Art

[0004] 2. Background complement system The complement system, an essential component of the innate immune system, plays a crucial role as a defense mechanism against invading pathogens, stimulating adaptive immune responses and helping to eliminate immune complexes and apoptotic cells. The complement system comprises three distinct pathways: the classical pathway, the lectin pathway, and the alternative pathway. C1q and mannose-binding lectin (MBL) are structurally related recognition molecules for the classical and lectin pathways, respectively. While IgM or clustered IgG acts as the primary ligand for C1q, MBL recognizes polysaccharides such as mannan. Ligand binding by C1q and MBL leads to the sequential activation of C4 and C2, forming the C3 convertases of the classical and lectin pathways, respectively. In contrast, activation of the alternative pathway does not require recognition molecules but can amplify the C3 activation induced by the classical or lectin pathway. Activation of any of these three pathways leads to the formation of inflammatory mediators (C3a and C5a) as well as membrane attack complexes (MACs) that cause cell lysis.

[0005] While the complement system plays a crucial role in many protective immune functions, complement activation is a key mediator of tissue damage in the processes of a wide range of autoimmune and inflammatory diseases (Ricklin and Lambris, "Complement-targeted therapeutics." Nat Biotechnol 2007; 25(11):1265-75 (Non-patent Literature 1)).

[0006] Naturally occurring peptides are essential signaling molecules that play important physiological roles in human biology in the form of neurotransmitters, hormones, growth factors, and antimicrobial agents [1]. Given their inherent specificity and efficient properties, this class of molecules has attracted considerable attention as human therapeutic agents for a variety of disease symptoms, with more than 60 approved for therapeutic use in the United States, Europe, and / or Japan as of March 2018, and 155 currently in clinical development [2]. The favorable properties of peptides offer considerable advantages over small molecules (<500 Da) which are often plagued by toxicity and off-target effects. Furthermore, compared to large protein-based molecules such as humanized monoclonal antibodies, peptides typically enjoy low-cost production and can often be chemically synthesized, thus avoiding costly and complex generation and purification. Often, naturally occurring peptides cannot be directly translated to therapeutic use due to suboptimal chemical and physical stability, as well as poor pharmacokinetics (half-life). Therefore, several technical approaches are frequently used to rationally design peptides into molecules suitable for human administration and leading to the development of newer drugs.

[0007] Complement regulators are needed. On the one hand, the complement system is a crucial host defense against pathogenic organisms. On the other hand, its unsuppressed activation can cause catastrophic host cell damage. Currently, despite the known morbidity and mortality associated with complement dysregulation in many disease processes, including autoimmune diseases such as systemic lupus erythematosus, myasthenia gravis, and multiple sclerosis, only two anti-complement therapies have recently been approved for use in humans: (1) eculizumab (Soliris®) and (2) ultomiris (Ravulizumab®), two humanized long-acting monoclonal antibodies against C5 used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH and aHUS are rare diseases that affect only a very small number of people. Currently, there are no approved complement regulators for more common disease processes in which dysregulated complement activation plays a central role. Dysregulation of complement activation can play a role in both chronic and acute disease symptoms.

[0008] The development of peptides to inhibit the classical, lectin, and alternative pathways of the complement system is needed because each of these three pathways has been shown to contribute to the processes of numerous autoimmune and inflammatory diseases. Specific blockade of the classical and lectin pathways is particularly necessary because both of these pathways are involved in ischemia-reperfusion-induced injury, among other diseases, in many animal models. Humans with alternative pathway deficiencies suffer from severe bacterial infections. Therefore, functional alternative pathways are essential for immune surveillance against invading pathogens.

[0009] The inventors have identified a novel family of peptides known as PIC1 (also known as EPICC peptides). PIC1 peptides possess multiple anti-inflammatory properties, including inhibition of the classical complement pathway, myeloperoxidase (MPO) inhibition, neutrophil extracellular trap (NET) inhibition, and intrinsic antioxidant and antibacterial activity [3-8]. The precursors of PIC1 peptides were initially based on the discovery that the 787-amino acid capsid protein sequence of human astrovirus type 1, an endemic non-enveloped icosahedral RNA virus [9] that causes gastroenteritis in human infants, can inhibit the activation of the classical complement pathway

[10] .

[0010] The PIC1 / EPICC molecular family comprises a collection of rationally designed peptides possessing several anti-inflammatory functional properties, including inhibition of the classical complement pathway, myeloperoxidase inhibition, neutrophil extracellular trapping inhibition, and antioxidant activity. The original PIC1 peptide is a 15-amino acid peptide sequence derived from scrambled astrovirus coat protein. The filename is TIFF2023549126000001.tif4128. The original PIC1 peptide is modified at the C-terminal monodisperse 24-mer pegylated moiety. TIFF2023549126000002.tif4128, this increases its water solubility. SEQ ID NO:2 sarcosine substitution scan shows that the substitution of isoleucine at position 8 with sarcosine is a peptide that is water-soluble without pegylation. It was revealed that this yields TIFF2023549126000003.tif4128 (as described in U.S. Patent No. 10,005,818 (Patent Document 1)). Solubility studies have shown that the PA-I8Sar peptide is amphiphilic. Various formulations of the PA-I8Sar peptide have been developed, including lipid-based formulations and formulations suitable for intravenous administration. Various formulations of PA-dPEG24 have also been developed, including formulations suitable for intravenous administration. [Prior art documents] [Patent Documents]

[0011] [Patent Document 1] U.S. Patent No. 10,005,818 [Non-patent literature]

[0012] [Non-Patent Document 1] Ricklin and Lambris, “Complement-targeted therapeutics.” Nat Biotechnol 2007; 25(11):1265-75 [Overview of the Initiative]

[0013] Brief summary of the invention As stated in the background section, there is a great need in the art to identify techniques for peptide-based inhibitors of different pathways of the complement system and to use this knowledge to develop novel therapeutic peptides. The present invention satisfies this need and other needs. Aspects of the present invention relate to pharmaceutically useful formulations of synthetic peptides in general, more specifically, synthetic peptides, for example, but not limited to, lipid-based formulations of peptides present in or associated with lipid micelles, and formulations suitable for intravenous administration.

[0014] In one aspect, the present invention provides a composition comprising a therapeutically effective amount of SEQ ID NO:3 and a lipid-based carrier. In some embodiments, the lipid-based carrier comprises lipid micelles. In some embodiments, the lipid-based carrier comprises a lipid emulsion, such as an Intralipid® carrier. In some embodiments, the Intralipid® carrier is present in an amount of about 10% w / v to about 20% w / v.

[0015] In related aspects, the present invention provides a composition comprising a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and at least one excipient. In some embodiments, the at least one excipient is suitable for intravenous administration. In some embodiments, the at least one excipient is selected from the group consisting of citric acid, ascorbic acid, amino acids, and combinations thereof. In some embodiments, citric acid comprises sodium citrate. In some embodiments, citric acid is present in an amount of about 1% w / v to about 5% w / v. In some embodiments, ascorbic acid comprises sodium ascorbate. In some embodiments, ascorbic acid is present in an amount of about 1% w / v to about 5% w / v. In some embodiments, the amino acid comprises L-methionine. In some embodiments, the amino acid is present in an amount of about 0.01% w / v to about 5% w / v.

[0016] In some embodiments of the compositions described herein, SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of about 0.001 to about 200 milligrams (mg / kg) per kilogram of body weight. In some embodiments of the compositions described herein, SEQ ID NO:2 and / or SEQ ID NO:3 is present in an amount of about 5 to about 160 mg / kg. In some embodiments of the compositions described herein, SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of about 1 mg / ml to about 100 mg / ml. In some embodiments of the compositions described herein, SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of about 10 mg / ml to about 80 mg / ml.

[0017] In related aspects, the present invention provides a method for altering cytokine expression, comprising the step of administering one of the compositions described herein to a subject in need of such alteration. In some embodiments, the administration includes parenteral administration. In some embodiments, the administration includes intravenous administration.

[0018] In related aspects, the present invention provides a method of treating or preventing a disease or condition, comprising the step of administering to a subject in need thereof any of the compositions described herein. In some embodiments, the administration includes parenteral administration. In some embodiments, the administration includes intravenous administration.

[0019] These and other objects, features and advantages of the present invention will become more apparent upon reading the following specification in conjunction with the accompanying description, claims, and drawings.

Brief Description of the Drawings

[0020] The accompanying drawings, which are incorporated herein and constitute a part of this specification, illustrate several aspects described below. [Figure 1] Figure 1 shows that PA-I8Sar formulated in Intralipid® (also referred to herein as RLS-0088) (the formulated PA-I8Sar is also referred to herein as lipo-RLS-0088) inhibited complement activation to the same extent as RLS-0088 formulated in histidine buffer. Values are expressed as a percentage of a positive control consisting of human O serum and AB red blood cells in GVBS++ buffer. The data shown are the mean ± standard error of the mean for n = 4. [Figure 2]Figures 2A-2B show that intravenous (IV) administration of lipo-RLS-0088 inhibited complement activation with higher functionality over time compared to RLS-0088. Male Wistar rats with indwelling jugular vein catheters were administered 200 mg / kg of RLS-0088 in Intralipid® or RLS-0088 in histidine buffer with 200 mg / kg of the compound as a single bolus IV injection. At various time points after injection (0.5, 2, 5, 60, 120, and 240 minutes), a fixed volume of blood was collected, plasma was isolated, and frozen at -70°C until analysis. Then, a C1q binding assay was performed. Figure 2A shows the results of the C1q binding assay with a maximum value of 6 mg / ml RLS-0088 on the Y-axis, while Figure 2B shows the same results with a maximum value of 0.8 mg / ml RLS-0088 on the Y-axis. [Figure 3] Figures 3A-3B show the effects of different excipients on the inhibition of hemolytic activity of RLS-0071 (3A) and RLS-0088 (3B) in an ABO incompatibility CH50 type assay. The data are the mean values + SEM of n = 3 independent experiments. [Figure 4] Figure 4 shows the appearance of various RLS-0088 formulations, where F indicates a freeze-thawed formulation and L indicates a lyophilized formulation. [Figure 5] Figure 5 shows the appearance of various RLS-0071 formulations, where F indicates a freeze-thawed formulation and L indicates a lyophilized formulation. **Modes for Carrying Out the Invention**

[0021] **Detailed Description of the Invention** As stated in the background section, there is a great need in the art to identify techniques for peptide-based inhibitors of different pathways of the complement system and to use this knowledge to develop novel therapeutic peptides. The present invention satisfies this need and other needs. Aspects of the present invention relate to pharmaceutically useful formulations of synthetic peptides in general, more specifically, synthetic peptides, for example, but not limited to, lipid-based formulations of peptides present in lipid micelles, and formulations suitable for intravenous administration.

[0022] To facilitate understanding of the principles and features of various embodiments of the present invention, several exemplary embodiments are described below. While exemplary embodiments of the present invention are described in detail, it should be understood that other embodiments are conceivable. Therefore, the present invention is not intended to be limited to the details of the composition and arrangement of components described below or in the examples. Other embodiments of the present invention are possible and can be implemented or carried out in various ways. Furthermore, specific terminology is used in the description of exemplary embodiments for clarity.

[0023] It should also be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless otherwise specified in the context. For example, a reference to one component is intended to include compositions of multiple components. A reference to a composition containing “a” component is intended to include other components in addition to the specified one. In other words, the terms “a,” “an,” and “the” do not indicate a limitation of quantity, but rather indicate the presence of “at least one” of the items referred to.

[0024] As used herein, the terms "and / or" can mean "and," "or," "exclusive or," "one," "some but not all," "neither," and / or this can mean "both." The term "or" is intended to mean inclusive "or."

[0025] Furthermore, terminology is used for clarity in the description of exemplary embodiments. Each term is intended to have its broadest meaning as understood by those skilled in the art and to include all technical equivalents that operate in a similar manner to achieve similar purposes. It should be understood that embodiments of the disclosed technology can be implemented without these specific details. Where otherwise, well-known methods, structures, and techniques are not described in detail so as not to obscure the understanding of this description. References to “one embodiment,” “a certain embodiment,” “example embodiment,” “several embodiments,” “a particular embodiment,” and “various embodiments” indicate that embodiments of the disclosed technology described in this way may include certain features, structures, or characteristics, but not all embodiments necessarily include those features, structures, or characteristics. Furthermore, repeated use of the phrase “in one embodiment” does not necessarily refer to the same embodiment, although it may.

[0026] As used herein, the term “about” should be interpreted as referring to both the number designated as the endpoint of any range. Any reference to a range should be considered as supporting any subset within the range. A range can be expressed herein as “about,” “approximately,” or “substantially” from a particular value and / or “about,” “approximately,” or “substantially” to another particular value. Where such a range is expressed, other exemplary embodiments include from a particular value and / or to another particular value. Furthermore, the term “about” means within an acceptable margin of error for a particular value determined by those skilled in the art, which is considered to depend in part on how the value is measured or determined, i.e., the limitations of the measuring system. For example, “about” may mean within an acceptable standard deviation according to convention in the art. Alternatively, “about” may mean a range of up to ±20%, preferably up to ±10%, more preferably up to ±5%, and more preferably even further up to ±1% of a given value. Or, particularly for biological systems or processes, the term may mean within one order of magnitude of the value, preferably up to twice the value. Where specific values ​​are mentioned in this application and claims, unless otherwise stated, the term “about” is implicit and in this context means that the value is within the acceptable margin of error.

[0027] Throughout this disclosure, various aspects of the invention may be presented in range form. It should be understood that the range form is merely for convenience and brevity and should not be interpreted as an inflexible limitation on the scope of the invention. Therefore, the range description should be considered to specifically disclose all possible subranges and individual numbers within the range. For example, a range description such as 1–6 should be considered to specifically disclose subranges such as 1–3, 1–4, 1–5, 2–4, 2–6, 3–6, etc., as well as individual numbers within the range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the width of the range.

[0028] Similarly, as used herein, characterizations such as "substantially absent" or "substantially pure" may include both "at least substantially absent" or "at least substantially pure" and "completely absent" or "completely pure."

[0029] "Comprising," "containing," or "including" means that at least the specified compound, element, particle, or process step is present in the composition, article, or method, and does not exclude the presence of other compounds, materials, particles, or process steps, even if those other compounds, materials, particles, or process steps have the same function as the specified one.

[0030] Throughout this description, various components with specific values ​​or parameters may be identified, but these items are provided in exemplary embodiments. In fact, exemplary embodiments do not limit the various aspects and concepts of the invention, as many comparable parameters, sizes, ranges, and / or values ​​can be implemented. Terms such as “first,” “second,” “primary,” “secondary,” etc., do not indicate any order, quantity, or importance, but rather are used to distinguish one element from another.

[0031] It should be noted that terms such as “particularly,” “preferably,” “typically,” “generally,” and “often” are not used herein to limit the scope of the claimed invention or to imply that certain features are decisive, essential, or even more important to the structure or function of the claimed invention. Rather, these terms are intended to simply highlight alternative or further features that may or may not be available in particular aspects of the invention. It should also be noted that terms such as “substantially” and “about” are used herein to indicate the inherent degree of uncertainty that may arise from any quantitative comparison, value, measurement, or other expression.

[0032] The dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​listed. Instead, unless otherwise specified, each such dimension is intended to mean both the listed value and a functionally equivalent range around that value. For example, a dimension disclosed as "50 mm" is intended to mean "approximately 50 mm."

[0033] It should also be understood that the reference to one or more process steps does not preclude the presence of further or intervening process steps between those explicitly identified steps. Similarly, it should be understood that the reference to one or more components in a composition does not preclude the presence of further components other than those explicitly identified.

[0034] The materials described below as constituting various elements of the present invention are intended to be illustrative and not limiting. Many suitable materials that would perform the same or similar functions as those described herein are intended to be included within the scope of the present invention. Other such materials not described herein include, but are not limited to, materials developed after the development of the present invention. Any dimensions listed in the various drawings are for illustrative purposes only and are not intended to be limiting. Other dimensions and proportions are intended to be contemplated and included within the scope of the present invention.

[0035] As used herein, the terms “subject” or “patient” refer to mammals and, not limited to, humans and veterinary animals. In preferred embodiments, the subject is human.

[0036] As used herein, the term “combination” of the synthetic peptide and at least one second pharmaceutically active ingredient according to the claimed invention means that at least two, but any desired combination of, the compounds are delivered simultaneously or sequentially (e.g., within 24 hours). When used to treat various diseases, the compositions and methods of the present invention are intended to be available in conjunction with other therapeutic methods / agents suitable for the same or similar diseases. Such other therapeutic methods / agents may be co-administered (simultaneously or sequentially) to produce additive or synergistic effects. Due to additive or synergistic effects, the appropriate therapeutically effective dosage for each agent can be reduced.

[0037] A "disease" is a health condition in which the subject is unable to maintain homeostasis, and if the disease does not improve, the subject's health continues to deteriorate. In contrast, a "disability" is a health condition in which the subject can maintain homeostasis, but the subject's health condition is less desirable than if there were no disability. Even if left untreated, a disability does not necessarily lead to a further decline in the subject's health condition.

[0038] The term "treatment" of a condition, disorder, or state includes: (1) preventing or delaying the onset of at least one clinical or quasi-clinical symptom of a condition, disorder, or state occurring in a subject who is currently suffering from or susceptible to such a condition, disorder, or state, but has not yet experienced or exhibited any clinical or quasi-clinical symptoms of the condition, disorder, or state; or (2) inhibiting the condition, disorder, or state, i.e., stopping, reducing, or delaying the onset or recurrence of the disease (in the case of maintenance treatment) or at least one clinical or quasi-clinical symptom thereof; or (3) reducing the disease, i.e., causing the regression of at least one clinical or quasi-clinical symptom of the condition, disorder, or state. The benefit to the subject being treated is either statistically significant or at least perceived by the patient or physician.

[0039] As used herein, the term “therapeutic” means treatment and / or prevention. Therapeutic effects are obtained by suppression, reduction, remission, or eradication of the disease condition.

[0040] As used herein, the term “therapeutically effective” as applied to dose or quantity means the amount of a compound or pharmaceutical composition that is sufficient to produce, when administered to a subject, to treat (e.g., prevent or improve) a situation, disorder, or condition. “Therapeutically effective amount” is considered to vary depending on the compound or bacterium or analogue administered, as well as the disease and its severity, and the age, weight, physical condition, and responsiveness of the mammal being treated.

[0041] When used in connection with the compositions of the present invention, the phrase “pharmaceutically acceptable” refers to molecular entities and other components of such compositions that are physiologically tolerable and typically do not produce adverse reactions when administered to mammals (e.g., humans). Preferably, as used herein, the term “pharmaceutically acceptable” means that it is approved by federal or state regulatory authorities for use in mammals, more particularly in humans, or that it is listed in the United States Pharmacopeia or other commonly accepted pharmacopoeias.

[0042] The term “pharmaceutical carrier” or “pharmaceutically acceptable carrier” refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered. Such pharmaceutical carriers may be sterile liquids, such as water, and oils, such as petroleum, animal, vegetable, or synthetic sources, such as peanut oil, soybean oil, mineral oil, or sesame oil. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably used as carriers, especially for injectable solutions. Alternatively, the pharmaceutical carrier may be a solid dosage form carrier containing, but not limited to, one or more binders (for compressed pills), flow enhancers, encapsulating agents, flavoring agents, and coloring agents. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E.W. Martin.

[0043] The term “analog” or “functional analog” refers to an associated modified form of a polypeptide in which at least one amino acid substitution, deletion, or addition has been made so that the analog retains substantially the same biological activity as the unmodified form in vivo and / or in vitro.

[0044] The terms “sequence identity” and “identity percentage” are used interchangeably herein. In this invention, to determine the identity percentage of two amino acid sequences or two nucleic acid sequences, it is defined herein that the sequences are aligned for the purpose of optimal comparison (for example, gaps can be introduced in the sequence of the first amino acid or nucleic acid for optimal alignment with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotide residues at corresponding amino acid or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid or nucleotide residue as the corresponding position in the second sequence, then the molecules are identical at that position. The identity percentage between the two sequences is a function of the number of identical positions common to these sequences (i.e., identity % = number of identical positions / total number of positions (i.e., overlapping positions) × 100). Preferably, the two sequences are of the same length.

[0045] Several different computer programs are available to determine the degree of identity between two sequences. For example, the comparison of sequences and the determination of the identity percentage between two sequences can be achieved using mathematical algorithms. In a preferred embodiment, the identity percentage between two amino acid sequences or nucleic acid sequences is determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)), which is incorporated into the GAP program of the Accelrys GCG software package (available at www.accelrys.com / products / gcg), using either a Blosum 62 matrix or a PAM250 matrix, as well as gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6. While these different parameters are expected to yield slightly different results, the overall identity percentage of the two sequences will not change significantly if different algorithms are used.

[0046] Sequence comparisons can be performed over the full length of the two sequences being compared, or over fragments of the two sequences. Typically, the comparison is thought to be performed over the full length of the two sequences being compared. However, sequence identity can be performed over regions of, for example, 20, 50, 100, or more consecutive amino acid residues.

[0047] In the art, "sequence identity" refers to the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, i.e., a reference sequence, and a given sequence that is compared to the reference sequence. Sequence identity is determined by comparing a given sequence to a reference sequence after the sequences have been optimally aligned to yield the highest degree of sequence similarity, which can be determined by matching strings of such sequences. During such alignment, sequence identity is checked position by position; for example, sequences are "identical" at a particular position if they have identical nucleotides or amino acid residues at that position. The sequence identity percentage is then obtained by dividing the total number of such identical positions by the total number of nucleotides or residues in the reference sequence. Sequence identity is incorporated herein by reference, but is not limited to, the teachings of which are included herein by reference: Computational Molecular Biology, Lesk, AN, ed., Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073. It can be easily calculated by known methods, including those described in (1988).A preferred method for determining sequence identity is designed to obtain the greatest match between the sequences being tested. Methods for determining sequence identity are systematized in publicly available computer programs that determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, SF et al., J. Molec. Biol., 215:403-410 (1990)). The BLASTX program is publicly available from NCBI and other sources (its teachings are incorporated herein by reference: BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, Md. 20894, Altschul, SF et al., J. Molec. Biol., 215:403-410). (1990)). These programs optimally align sequences using default gap weights to achieve the highest level of sequence identity between a given sequence and a reference sequence. As one example, a given polynucleotide sequence is intended to be identical to the reference sequence, except that the given polynucleotide sequence may contain up to 5, 4, 3, 2, 1, or 0 point mutations per 100 nucleotides of the reference sequence.In other words, in a polynucleotide having a nucleotide sequence with at least 95% sequence identity to a reference nucleotide sequence, for example, at least 96%, 97%, 98%, 99%, or 100%, up to 5%, 4%, 3%, 2%, 1%, or 0% of the nucleotides of the reference sequence can be deleted and replaced with other nucleotides, or up to 5%, 4%, 3%, 2%, 1%, or 0% of the total nucleotides of the reference sequence can be inserted into the reference sequence. These mutations in the reference sequence can occur at the 5' or 3' terminal positions of the reference nucleotide sequence, or dispersed individually among nucleotides in the reference sequence or in one or more consecutive groups within the reference sequence, at any location between these terminal positions. Similarly, by a polypeptide having a given amino acid sequence having sequence identity of at least, for example, 95%, for example, at least 96%, 97%, 98%, 99%, or 100% with respect to a reference amino acid sequence, the given amino acid sequence of the polypeptide is intended to be identical to the reference sequence, except that the given polypeptide sequence may contain up to 5, 4, 3, 2, 1, or 0 amino acid changes per 100 amino acids of the reference amino acid sequence. In other words, to obtain a given polypeptide sequence having at least 95% sequence identity with a reference amino acid sequence, for example, at least 96%, 97%, 98%, 99%, or 100%, up to 5%, 4%, 3%, 2%, 1%, or 0% of the amino acid residues of the reference sequence can be deleted or substituted with other amino acids, or up to 5%, 4%, 3%, 2%, 1%, or 0% of the total number of amino acid residues in the reference sequence can be inserted into the reference sequence. These changes to the reference sequence can occur at the amino or carboxyl terminal positions of the reference amino acid sequence, or dispersed individually between residues in the reference sequence or in one or more consecutive groups within the reference sequence, at any location between these terminal positions. Preferably, the positions of non-identical residues are distinguished by conservative amino acid substitutions.However, when determining sequence identity, conservative substitutions are not included as matches.

[0048] As used herein, the term “immune response” includes innate immune responses, T cell-mediated immune responses, and / or B cell-mediated immune responses. Exemplary immune responses include T cell responses, e.g., cytokine production and cytotoxicity, and B cell responses, e.g., antibody production. Furthermore, the term “immune response” includes immune responses indirectly affected by T cell activation, e.g., antibody production (humoral response) and cytokine-responsive cell activation, e.g., macrophage activation. Immune cells involved in the immune response include lymphocytes, such as B cells and T cells (CD4+, CD8+, Th1, and Th2 cells); antigen-presenting cells (e.g., professional antigen-presenting cells, such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and non-professional antigen-presenting cells, such as keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes); natural killer cells; myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes (e.g., neutrophils).

[0049] Examples of "parenteral" administration of immunogenic compositions include subcutaneous (sc), intravenous (iv), intramuscular (im), or intradermal (id) injection or infusion techniques.

[0050] In the field of medicine, the term "prevent" encompasses any activity that reduces the mortality or morbidity burden of a disease. Prevention can occur at primary, secondary, and tertiary levels. Primary prevention avoids the onset of the disease, while secondary and tertiary prevention encompasses activities aimed at reducing the negative effects of an already established disease by preventing disease progression and the appearance of symptoms, as well as by restoring function and reducing disease-related complications.

[0051] A "mutant" of the polypeptide according to the present invention may be (i) one or more amino acid residues substituted with conserved or non-conserved amino acid residues (preferably conserved amino acid residues), where such substituted amino acid residues may or may not be encoded in the genetic code; (ii) one or more modified amino acid residues, e.g., residues modified by substituent attachment; (iii) the polypeptide is an alternative splicing variant of the polypeptide of the present invention; (iv) a polypeptide fragment; and / or (v) the polypeptide fused with another polypeptide, e.g., a leader sequence or secretion sequence, or a sequence used for purification (e.g., a His tag) or a sequence used for detection (e.g., an Sv5 epitope tag). The fragment comprises a polypeptide produced by proteolytic cleavage (including multi-site proteolysis) of the original sequence. The mutant may be post-translationally or chemically modified. Such mutants are considered to be within the scope of the art from the teachings herein.

[0052] Within the scope of the present invention, the term "co-administration" is used to refer to the administration of a composition according to the present invention and another therapeutic agent simultaneously in one composition, simultaneously in different compositions, or consecutively (preferably within 24 hours).

[0053] According to the present invention, conventional molecular biology, microbiology, and recombinant DNA techniques within the scope of the art can be used. Such techniques are well described in the literature. Among the many available, for example, Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (referred to as "Sambrook et al., 1989" in this specification); DNA Cloning: A Practical Approach, Volumes I and II (DN Glover ed. 1985); Oligonucleotide Synthesis (MJ Gait ed. 1984); Nucleic Acid Hybridization (BD Hames & SJ Higgins eds. (1985); Transcription and Translation (BD Hames & SJ Higgins, eds. (1984); Animal Cell Culture (RI Freshney, ed. (1986); Immobilized Cells and Enzymes (IRL Press, (1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); FM Ausubel et al. (eds.), Current Protocols in See Molecular Biology, John Wiley & Sons, Inc. (1994).

[0054] The peptide composition of the present invention Modification of the amino acid structure of CP1 led to the discovery of further peptides that can regulate complement activation, such as C1q activity. In in vitro assays of classical complement pathway activation / inhibition, myeloperoxidase (MPO) inhibition, antioxidant activity, and NET activity inhibition, the parent molecule... Compared to TIFF2023549126000004.tif4128, modifications such as pegylation have been previously shown to enhance the solubility and potent inhibition of the peptide's biological activity. Peptides with a monodisperse 24-mer pegylated moiety at the C-terminus were found to be highly soluble and exhibit strong complement system inhibition. TIFF2023549126000005.tif4128. Sarcosine substitution of non-pegylated peptides was found to have similar solubility to pegylated peptides. TIFF2023549126000006.tif4128. Various formulations of PA-I8Sar were explored to develop formulations suitable for intravenous administration, including lipid-based formulations and formulations with excipients containing citrate (e.g., trisodium citrate dihydrate), ascorbic acid (e.g., sodium ascorbate), and / or amino acids (e.g., L-methionine). Formulations of PA-dPEG24 with excipients containing citrate (e.g., trisodium citrate dihydrate), ascorbic acid (e.g., sodium ascorbate), and / or amino acids (e.g., L-methionine) were also developed.

[0055] As used herein, the term "peptide" refers to a naturally occurring amino acid sequence, or a peptide mime, peptide analogue, and / or a synthetic derivative of about 15 amino acids based on SEQ ID NO:2 (e.g., pegylated peptides, but not limited to these). Furthermore, a peptide may be less than about 15 amino acid residues, for example, about 10 to about 15 amino acid residues, for example, a peptide of about 5 to about 10 amino acid residues. For example, peptide residues of amino acids 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 may also be peptides in the context of the present invention. A peptide may also be more than 15 amino acids, for example, 16, 17, 18, 19, and 20, or more amino acids.

[0056] The disclosed peptides can be formulated in a lipid-based carrier or with excipients suitable for intravenous administration. The lipid-based carrier may be Intralipid®, which can be used for parenteral nutritional supplementation in humans to enhance intravenous calorie intake and consists of an emulsion of lipid micelles. The peptides can associate with lipid micelles and, for example, be incorporated into a layer of lipid micelles. Excipients suitable for intravenous administration may include citrate (e.g., sodium citrate or sodium citrate dihydrate), ascorbic acid (e.g., sodium ascorbate), or amino acids (e.g., L-methionine).

[0057] Substitutions for amino acids in a peptide sequence can be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. Amino acids containing aromatic ring structures include phenylalanine, tryptophan, and tyrosine. Polar, neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine and lysine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. For example, one or more amino acid residues in a sequence can be substituted with other amino acids of similar polarity that act as functional equivalents, resulting in a silent change.

[0058] Conservative changes generally do not lead to significant changes in the structure and function of the resulting protein. Non-conservative changes are more likely to alter the structure, activity, or function of the resulting protein. For example, the peptides of this disclosure include one or more of the following conservative amino acid substitutions: aliphatic amino acids, e.g., replacement of alanine, valine, leucine, and isoleucine with another aliphatic amino acid; serine with threonine; threonine with serine; acidic residues, e.g., replacement of aspartic acid and glutamic acid with another acidic residue; residues with amide groups, e.g., replacement of asparagine and glutamine with another residue with an amide group; basic residues, e.g., replacement of lysine and arginine with another basic residue; and aromatic residues, e.g., replacement of phenylalanine and tyrosine with another aromatic residue.

[0059] Particularly preferred amino acid substitutions include the following: (a) Ala to Glu or vice versa, such that the negative charge can be reduced; (b) Lys relative to Arg, or vice versa, such that a positive charge can be maintained; (c) Ala relative to Arg, or vice versa, such that the positive charge can be reduced; (d) Glu to Asp or vice versa, such that a negative charge can be maintained; (e) Ser relative to Thr, or vice versa, such that the free -OH can be maintained; (f) Gln relative to Asn, or vice versa, such that free NH2 can be maintained; (g) Ile as a roughly equivalent hydrophobic amino acid to Leu or Val, or vice versa; (h) Phe for Tyr or vice versa, as roughly equivalent aromatic amino acids; and (i) Ala to Cys or vice versa, such that the disulfide bond is affected.

[0060] The amino acid substitutions in the peptide sequence are not limited to but can be selected from any amino acid, including alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, pyrrolidine, selenocysteine, serine, threonine, tryptophan, tyrosine, valine, N-formyl-L-methionine, sarcosine, or other N-methylated amino acids. In some embodiments, sarcosine is substituted for an amino acid in the peptide sequence.

[0061] In one aspect, the present invention provides lipid-based formulations of synthetic peptides that modulate the complement system and methods of using these peptides. In particular, in some embodiments, lipid-based formulations of synthetic peptides can bind to C1 and MBL, modulate C1 and MBL, and inactivate C1 and MBL, and thus efficiently inhibit the activation of the classical and lectin pathways at their earliest point while leaving alternative pathways intact. These lipid-based formulations of peptides have therapeutic value for selectively modulating and inhibiting the activation of C1 and MBL without affecting alternative pathways and can be used to treat diseases mediated by dysregulated activation of the classical and lectin pathways. In other embodiments, lipid-based formulations of peptides modulate the activation of the classical pathway but not the activation of the lectin pathway. Lipid-based formulations of peptides are useful for a variety of therapeutic indications, including, but not limited to, diseases of organs with high lipid content such as the brain and pancreas (e.g., hypoxic-ischemic encephalopathy (HIE), stroke, traumatic brain injury, pancreatitis). The lipid-based formulations of the present invention can also be used for subcutaneous depot administration for chronic inflammatory conditions, such as, but not limited to, lupus, anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis), Behçet's disease, autoimmune nephritis, and renal impairment.

[0062] In one aspect, the present invention provides intravenous formulations of synthetic peptides that modulate the complement system and methods of using these peptides. In particular, in some embodiments, intravenous formulations of synthetic peptides can bind to C1 and MBL, modulate C1 and MBL, and inactivate C1 and MBL, and thus efficiently inhibit the activation of the classical and lectin pathways at their earliest point while leaving alternative pathways intact. These intravenous formulations of peptides have therapeutic value for selectively modulating and inhibiting the activation of C1 and MBL without affecting alternative pathways and can be used to treat diseases mediated by dysregulated activation of the classical and lectin pathways. In other embodiments, intravenous formulations of peptides modulate the activation of the classical pathway but not the activation of the lectin pathway. Intravenous formulations of peptides are useful for a variety of therapeutic indications.

[0063] In one embodiment, the present invention provides a synthetic peptide derived from human astrovirus coat protein, the peptide comprising, for example, the amino acid sequence and modifications of SEQ ID NO:2, such as sarcosine substitution of SEQ ID NO:2, for example. In one embodiment, the present invention provides a lipid-based formulation of any of the peptides discussed herein, for example, SEQ ID NO:3, for example. In some embodiments, the lipid-based formulation comprises lipid micelles. In some embodiments, the lipid-based formulation comprises Intralipid®.

[0064] In one embodiment, the present invention provides a formulation of any of the peptides discussed herein, including, but not limited to, SEQ ID NO:3, that is suitable for intravenous administration. In one embodiment, the present invention provides an intravenous pharmaceutical formulation of any of the peptides discussed herein, including, but not limited to, SEQ IS NO:2 and / or SEQ ID NO:3, further comprising, for example, a further excipient suitable for intravenous administration, such as, for example, citrate (e.g., trisodium citrate dihydrate), ascorbic acid (e.g., sodium ascorbate), and / or an amino acid (e.g., L-methionine).

[0065] (Table 1) List of peptides of the present invention TIFF2023549126000007.tif51161

[0066] In other embodiments, synthetic peptides can alter cytokine expression. In some embodiments, the present invention provides a method for altering cytokine expression, comprising the step of administering a composition containing a therapeutically effective amount of a lipid-based formulation of a synthetic peptide containing SEQ ID NO:3 to a subject in need. In some embodiments, the lipid-based formulation contains lipid micelles. In some embodiments, SEQ ID NO:3 is present within the lipid micelles. In some embodiments, the lipid-based formulation contains Intralipid® and SEQ ID NO:3.

[0067] In some embodiments, the present invention provides a method for altering cytokine expression, comprising the step of intravenously administering a pharmaceutical formulation containing a therapeutically effective amount of a synthetic peptide comprising SEQ ID NO:2 or SEQ ID NO:3 to a subject in need. In some embodiments, the pharmaceutical formulation may include excipients, carriers, and other components suitable for intravenous administration. In some embodiments, the pharmaceutical formulation may contain a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and citrate (e.g., sodium citrate or sodium citrate dihydrate, etc., but not limited to these). In one embodiment, the excipient is an antioxidant suitable for use in adult subjects (e.g., citrate, trisodium citrate, trisodium citrate trihydrate). In one embodiment, the excipient is an antioxidant suitable for use in children or infants (e.g., ascorbic acid such as sodium ascorbate, and / or an amino acid such as L-methionine). In some embodiments, citrate may be present in amounts of approximately 1% w / v to approximately 5% w / v, including approximately 1% w / v to approximately 2.5% w / v. In some embodiments, the pharmaceutical formulation contains a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and ascorbic acid (e.g., sodium ascorbate, not limited to any other). In some embodiments, ascorbic acid may be present in amounts of approximately 1% w / v to approximately 5% w / v, including approximately 2.5% w / v to approximately 4.5% w / v. In some embodiments, the pharmaceutical formulation contains a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and an amino acid (e.g., L-methionine, not limited to any other). In some embodiments, the amino acid may be present in amounts of 0.01% w / v to approximately 5% w / v, including approximately 0.1% w / v to approximately 1% w / v.

[0068] The disclosed peptides can selectively modulate C1q and MBL activation without affecting alternative pathway activity, and are therefore ideal for the prevention and treatment of diseases mediated by dysregulated activation of classical and lectin pathways. Specific blockade of classical and lectin pathways is particularly necessary because both of these pathways are involved in ischemia-reperfusion-induced injury in many animal models. [Castellano et al., “Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.” Am J Pathol. 2010; 176(4):1648-59; Lee et al., “Early complement factors in the local tissue immunocomplex generated during intestinal ischemia / reperfusion injury.” Mol. Immunol. 2010 February; 47(5):972-81; Tjernberg, et al., “Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation.” Transplantation. 2008 Apr. 27; 85(8):1193-9; Zhang et al. “The role of natural IgM in "Myocardial ischemia-reperfusion injury." J Mol Cell Cardiol. 2006 July; 41(1):62-7). Alternative pathways are essential for immune surveillance against invading pathogens, and individuals lacking these pathways suffer from severe bacterial infections.By binding to and inactivating C1q and MBL, this peptide can efficiently regulate the activation of classical and lectin pathways while leaving alternative pathways intact.

[0069] As used herein, the term “modulate” means (i) controlling, reducing, inhibiting, or regulating the biological function of an enzyme, protein, peptide, factor, by-product, or derivative thereof, either individually or in complex; (ii) reducing the amount of a biological protein, peptide, or derivative thereof, either in vivo or in vitro; or (iii) disrupting a biological chain of events, cascades, or pathways known to involve a series of related biological or chemical reactions. Thus, the term “modulate” can be used, for example, to describe reducing the amount of a single component of a complement cascade compared to a control sample, reducing the rate or total amount of formation of a component or a complex of components, or reducing the overall activity of a complex process or series of biological reactions, which may result in consequences such as cell lysis, conversion of convertase enzymes, formation of complement-derived membrane attack complexes, inflammation, or inflammatory diseases. In in vitro assays, the term “modulate” can refer to a measurable change or reduction of a certain biological or chemical event, but those skilled in the art will recognize that the measurable change or reduction does not need to be absolute for it to be “modulate.”

[0070] In some embodiments, the present invention relates to therapeutically active peptides having the effect of modulating the complement system.

[0071] Pharmaceutical composition of the present invention This disclosure provides a pharmaceutical composition capable of modulating the complement system, comprising at least one peptide as described above and at least one pharmaceutically acceptable carrier, diluent, stabilizer, or excipient. The pharmaceutically acceptable carrier, excipient, or stabilizer is non-toxic to the recipient at the dosage and concentration used. These may be solid, semi-solid, or liquid. The pharmaceutical composition of the present invention may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, or syrups.

[0072] The pharmaceutical compositions of the present invention are prepared by mixing the peptide of appropriate purity with a pharmaceutically acceptable carrier, diluent, or excipient. Examples of formulations and methods for preparing such formulations are well known in the art. The pharmaceutical compositions of the present invention are useful as prophylactic and therapeutic agents for various disorders and diseases as described above. In one embodiment, the composition contains a therapeutically effective amount of the peptide. In another embodiment, the composition contains at least one other active ingredient effective in modulating the complement system. In another embodiment, the composition contains at least one other active ingredient effective in treating at least one disease associated with the complement system. In yet another embodiment, the composition contains at least one other active ingredient effective in treating at least one disease not associated with the complement system. As used herein, the term “therapeutably effective amount” means the total amount of each active ingredient sufficient to demonstrate a benefit to the subject.

[0073] The therapeutically effective amount of peptide varies depending on several factors, such as the condition being treated, the severity of the condition, the time of administration, the route of administration, the elimination rate of the peptide used, the duration of treatment, the concomitant therapies involved, and the age, sex, weight, and condition of the subject. Those skilled in the art can determine the therapeutically effective amount. Therefore, those skilled in the art may need to titrate the dosage and modify the route of administration to obtain the maximum therapeutic effect.

[0074] The effective daily dose is generally in the range of approximately 0.001 to 200 milligrams (mg / kg) per kilogram of body weight, including approximately 5 to 160 mg / kg, approximately 10 to 160 mg / kg, approximately 40 mg / kg to 160 mg / kg, and approximately 40 mg / kg to 100 mg / kg. This dose can be achieved with a regimen of 1 to 6 doses per day. The effective dosage is generally in the range of approximately 1 mg / ml to 100 mg / ml, including approximately 10 mg / ml to 80 mg / ml. The effective dosage may depend on further components contained in the pharmaceutical composition. Alternatively, optimal treatment can be achieved with a sustained-release formulation using a lower-frequency dosing regimen. The effective dosage may depend on the age of the subject. For example, children or infants may require a lower dosage of the pharmaceutical composition compared to adults, though this is not limited to children or infants. The effective dosage for children or infants may be approximately 10 mg / ml. The effective dosage for adults may be approximately 80 mg / ml.

[0075] In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a lipid-based formulation of SEQ ID NO:3 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

[0076] In another aspect, the present invention provides an intravenous pharmaceutical formulation comprising a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and at least one pharmaceutically acceptable carrier, diluent, or excipient suitable for intravenous administration. In one embodiment, the excipient may include citric acid (e.g., trisodium citrate dihydrate), ascorbic acid (e.g., sodium ascorbate), and / or an amino acid (e.g., L-methionine). In one embodiment, the excipient is an antioxidant (e.g., citric acid, trisodium citrate, trisodium citrate trihydrate) suitable for use in adult subjects. In one embodiment, the excipient is an antioxidant (e.g., ascorbic acid such as sodium ascorbate, and / or an amino acid such as L-methionine) suitable for use in children or infants.

[0077] The compositions of the present invention may include carriers and / or excipients. While the compounds of the present invention may be used as is for therapeutic purposes, it may be preferable to administer them in a pharmaceutical formulation, for example, in a mixture with appropriate pharmaceutical excipients and / or carriers selected with respect to the intended route of administration and standard pharmaceutical practice. The excipients and / or carriers must be compatible with the other components of the formulation and “acceptable” in the sense that they are not harmful to their recipients. Acceptable excipients and carriers for therapeutic use are well known in the pharmaceutical field and are described, for example, in Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins (AR Gennaro edit. 2005). The choice of pharmaceutical excipients and carriers may be selected with respect to the intended route of administration and standard pharmaceutical practice. Oral formulations readily accommodate further mixtures. Solid dosage forms for oral administration may also be used, and examples of solid dosage forms for oral administration include capsules, tablets, caplets, pills, lozenges, powders, and granules. Suitable excipients, though not limited to specific examples, include diluents, buffers (e.g., sodium bicarbonate), preservatives, stabilizers, binders, compressors, lubricants, dispersion enhancers, disintegrants, antioxidants, flavorings, sweeteners, and colorants. Those skilled in the art can easily prepare suitable solutions.

[0078] In any one embodiment of the compositions of the present invention, the composition is formulated for delivery by routes such as oral, topical, rectal, mucosal, sublingual, nasogastric, naso / oro gastric forced feeding, parenteral, intraperitoneal, intradermal, transdermal, intrathecal, nasogastric, and intratracheal administration. In any one embodiment of the compositions of the present invention, the composition is in the form of a liquid, foam, cream, spray, powder, or gel. In any one embodiment of the compositions of the present invention, the composition comprises a buffering agent (e.g., sodium bicarbonate).

[0079] The administration of compounds and compositions in the method of the present invention can be achieved by any method known in the art. Non-limiting examples of useful routes of delivery include oral, rectal, fecal (by enema), and nasogastric / oral forced feeding, as well as parenteral, intraperitoneal, intradermal, transdermal, intrathecal, nasogastric, and intratracheal administration. The activator may be systemic after administration, or localized by regional administration, intramural administration, or by the use of an implant that acts to retain the active dose at the implantation site.

[0080] The effective dosage of the compounds and formulations of the present invention can vary widely depending on the nature of the disease, the patient's medical history, the frequency of administration, the mode of administration, and the elimination of the active ingredient from the host. The initial dose can be high, and subsequent maintenance doses can be low. Doses can be administered at low frequencies, such as weekly or bi-weekly, to maintain an effective dosage level, or they can be divided into smaller doses and administered daily, every two weeks, etc. It is conceivable that various doses may be effective in achieving therapeutic effects. While the compounds of the present invention can be used as is for therapeutic purposes, it may be preferable to administer them in a pharmaceutical formulation, for example, in a mixture with appropriate pharmaceutical excipients, diluents, or carriers selected in relation to the intended route of administration and standard pharmaceutical practices. The excipients, diluents, and / or carriers must be compatible with the other components of the formulation and “acceptable” in the sense that they are not harmful to their recipients. Acceptable excipients, diluents, and carriers for therapeutic use are well known in the pharmaceutical field and are described, for example, in Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins (AR Gennaro edit. 2005). The choice of pharmaceutical excipients, diluents, and carriers may be selected in relation to the intended route of administration and standard pharmaceutical practice. There are no physical limitations on the delivery of the formulations of the present invention, but for ease and convenience, and because oral formulations readily accommodate further mixtures such as milk, yogurt, and infant formula, oral delivery is preferred for delivery to the gastrointestinal tract.

[0081] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that make the formulation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous suspensions that may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives.

[0082] The solution or suspension may contain any combination of the following components: sterile diluents, for example, water for injection, saline solution, non-volatile oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, for example, benzyl alcohol and methylparaben; antioxidants, for example, ascorbic acid and sodium bisulfite; chelating agents, for example, ethylenediaminetetraacetic acid (EDTA); buffers, for example, acetic acid, citric acid, and phosphoric acid; and agents for adjusting tonicity, for example, sodium chloride or dextrose.

[0083] If the agent exhibits insufficient solubility, methods for solubilizing the agent can be used. Such methods are known to those skilled in the art and are not limited to, but include the use of a cosolvent, such as dimethyl sulfoxide (DMSO), a surfactant, such as TWEEN® 80, or dissolution in an aqueous sodium bicarbonate solution. In the formulation of effective pharmaceutical compositions, pharmaceutically acceptable derivatives of the agent may also be used.

[0084] The composition may, along with the activator, include, for example, not limited to: diluents, e.g., lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; lubricants, e.g., magnesium stearate, calcium stearate, and talc; and binders, e.g., starch, natural rubber, e.g., acacia gum gelatin, glucose, molasses, polyvinylpyrrolidone, cellulose, and their derivatives, povidone, crospovidone, and other such binders known to those skilled in the art. Liquid pharmaceutically acceptable compositions may be prepared, for example, by dissolving, dispersing, or mixing the activator and any pharmaceutically acceptable auxiliaries in a carrier, for example, not limited to, water, saline solution, aqueous dextrose, glycerol, glycol, ethanol, etc., thereby forming a solution or suspension. If desired, the administered pharmaceutical composition may also contain small amounts of non-toxic auxiliary substances, such as wetting agents, emulsifiers, or solubilizers, pH buffering agents, for example, not limited to, acetic acid, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, sodium triethanolamine acetate, triethanolamine oleate, and other such agents. Practical methods for preparing such dosage forms are known or will be apparent to those skilled in the art (e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975). In any case, the administered composition or formulation shall contain an amount of the active agent sufficient to alleviate the symptoms of the subject being treated.

[0085] The activator or pharmaceutically acceptable derivative can be prepared using a carrier that protects the agent from rapid elimination from the body, such as a sustained-release formulation or a coating. The composition may contain other activators to obtain a desired combination of properties.

[0086] Parenteral administration generally features, and is intended herein, injection by subcutaneous, intramuscular, or intravenous injection. The injection solution can be prepared in conventional forms, either as a liquid solution or suspension, as a solid suitable for the liquid solution or suspension before injection, or as an emulsion. Suitable excipients include, but are not limited to, water, saline, dextrose, glycerol, or ethanol. Furthermore, if desired, the administered pharmaceutical composition may also contain small amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, and cyclodextrin.

[0087] Lyophilized powders can be reconstituted for administration of solutions, emulsions, and other mixtures, or formulated as solids or gels. Sterile lyophilized powders are prepared by dissolving the agents provided herein or pharmaceutically acceptable derivatives thereof in a suitable solvent. The solvent may contain excipients to improve stability, or other pharmacological components of the powder or the reconstituted solution prepared from the powder. Excipients that may be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable agents. The solvent may also contain a buffer, e.g., citrate, sodium, or potassium phosphate, or other such buffers known to those skilled in the art, typically at a nearly neutral pH. The desired formulation is then provided by sterile filtration of the solution, followed by lyophilization under standard conditions known to those skilled in the art. Generally, the resulting solution can be distributed into vials for lyophilization. Each vial may, for example, contain, non-limiting, a single dose (10-1000 mg, e.g., 100-500 mg) or multiple doses of the preparation. The lyophilized powder can be stored under appropriate conditions, for example, at approximately 4°C to room temperature. Reconstitution of this lyophilized powder with sterile water for injection provides a formulation for parenteral administration.

[0088] Combination therapy A further aspect of the present invention provides a method for modulating the complement system, comprising the step of administering the pharmaceutical formulations of the present invention to a target. The pharmaceutical formulations of the present invention can be administered as a sole active pharmaceutical agent, but they can also be used in combination with one or more therapeutic or prophylactic agents effective in modulating the complement system. In this aspect, the method of the present invention includes the step of administering the pharmaceutical formulations of the present invention before, simultaneously with, and / or after, one or more further therapeutic or prophylactic agents effective in modulating the complement system.

[0089] The pharmaceutical formulations of the present invention can be administered in combination therapy with further agents, either together or separately, or by combining the pharmaceutical formulation and further agents in a single composition. The dosage is administered and adjusted to achieve maximum regulation of the complement system. For example, both the pharmaceutical formulation and further agents are typically present at dosage levels between about 10% and about 150%, more preferably between about 10% and about 80%, of the dosage typically administered in a monotherapy regimen. [Examples]

[0090] The present invention is also described and illustrated through the following embodiments. However, the use of these and other embodiments anywhere in this specification is illustrative only and does not in any way limit the scope and meaning of the present invention or any exemplified terms. Similarly, the present invention is not limited to any particular preferred embodiment described herein. In fact, many modifications and variations of the present invention may become apparent to those skilled in the art by reading this specification, and such variations can be made without departing in spirit or scope from the present invention. Accordingly, the present invention should be limited only by the terms of the appended claims, together with the entire scope of equivalents to which the appended claims are entitled.

[0091] Example 1: Lipid-based formulation of PA-I8Sar TIFF2023549126000008.tif4128 was solubilized in 20% Intralipid® to obtain a homogeneous solution. During centrifugation, the PA separated into a lipid layer and an aqueous layer. Interestingly, at a concentration of 2 mg / ml, 60% of the PA associated with the lipid layer, while only 40% remained in the aqueous phase. When this mixture was left at 4°C for 48 hours, it became a paste with sufficient viscosity for topical application.

[0092] When PA-dPEG24 (RLS-0071; SEQ ID NO:2) or PA-I8Sar (RLS-0088; SEQ ID NO:3) was solubilized in 20% Intralipid®, or when they were mixed with 20% Intralipid® in a 1:1 ratio in their soluble form (resulting in 10% Intralipid®), both yielded homogeneous solutions that did not separate well upon centrifugation. In vitro assays tested the complement activation inhibitory ability of lipo-RLS-0088, and surprisingly, it was found that this ability was maintained and similar to that of RLS-0088 in solution (Figure 1). This was unexpected, considering that in lipo-RLS-0088, the active pharmacological agent was able to interact with hydrophilic complement components in solution and inhibit their activation, even though it was associated with micelles. Considering that in vitro activity was preserved, the inhibitory effect of lipo-RLS-0088 was tested in vivo by IV injection into adult rats. The control group consisted of different sets of adult rats injected with the same dose of RLS-0088 in solution. Pharmacodynamically, rats treated with IV lipo-RLS-0088 showed a four-fold increase in functionality over time (measured by C1q binding assay) compared to rats treated with the same dose of IV RLS-0088 (Figures 2A-2B).

[0093] method ABO hemolysis assay For the hemolytic complement assay, human red blood cells (RBCs) derived from type AB donors were purified, washed, and processed into 1.0 × 10⁶ units. 9 The concentration was standardized to cells / ml. Human serum from a type O donor at a final concentration of 10% was mixed with 1.0 mM peptide and GVBS was used. ++ and 5.0×10 7 The volume was increased to 0.250 ml using one RBC. The sample was incubated at 37°C for 1 hour, then spun at 3,000 rpm for 5 minutes, the supernatant was collected, and read at 412 nm.

[0094] In vivo testing Male Wistar rats with indwelling jugular vein catheters were administered a single bolus IV infusion of 200 mg / kg of RLS-0088 in Intralipid® or 200 mg / kg of the compound in histidine buffer. At various time points after infusion (0.5, 2, 5, 60, 120, and 240 minutes), a fixed volume of blood was collected, the plasma was isolated, and frozen at -70°C until analysis. After the final blood collection, the animals were sacrificed and macroscopic necropsy was performed. Subsequently, a C1q binding assay was performed.

[0095] C1q binding assay Immunlon-2 HB ELISA plates were coated overnight at 4°C with 1 μg / ml C1q in bicarbonate buffer. The plates were washed with PBS-T (phosphate-buffered saline + 0.1% Tween) and then blocked at room temperature for 2 hours in 1% gelatin / PBS. After washing, the plates were incubated at room temperature for 1 hour with plasma samples diluted in 1% gelatin / PBS, and then washed. The plates were then treated with pegylated (PA) peptides. Rabbit antibodies produced against TIFF2023549126000009.tif4128 were probed at a 1:1000 ratio in 1% gelatin / PBS at room temperature for 1 hour. Subsequently, goat anti-rabbit HRP (Sigma Aldrich, St Louis, MO) was probed at a 1:1000 ratio in 1% gelatin / PBS at room temperature for 1 hour, with a washing step in between. After adding the TMB substrate solution to the wells, the reaction was stopped using 1N H2SO4, and the plate was read at 450 nm using a BioTek Synergy HT plate reader.

[0096] Example 2: Intravenous formulation of PA-I8Sar PA-dPEG24 (RLS-0071) and PA-I8Sar (RLS-0088) were successfully formulated in a liquid containing histidine buffer. To develop formulations of these two molecules suitable for intravenous administration to pediatric and adult patients, PA-dPEG24 and PA-I8Sar were formulated using the following excipients: 2.5% w / v citric acid (trisodium citrate dihydrate) for adult formulations 2.88% w / v ascorbic acid (sodium ascorbate) for infant formulations 0.16% w / v L-methionine buffer for infant formulations.

[0097] Regarding citrate buffer conditions, PA-dPEG24 and PA-I8Sar were formulated at a concentration of 80 mg / ml at pH 6.8. For PA-dPEG24, it was observed that the preparation would begin to gel if not kept on ice. This gelation behavior was not observed for PA-I8Sar.

[0098] PA-dPEG24 and PA-I8Sar were formulated at a concentration of 10 mg / ml at pH 6.8 under the conditions of ascorbic acid and L-methionine.

[0099] To determine whether these various excipients have any effect on the functional activity of PA-dPEG24 and PA-I8Sar, formulated peptides were tested in a hemolysis assay to determine their ability to inhibit complement activity. For the hemolysis complement assay, as described above, human erythrocytes (RBCs) from AB donors were purified, washed, and 1 × 10⁶ 9 The concentration was standardized to cells / ml. Human serum from a type O donor at a final concentration of 20% was mixed with gradually increasing concentrations of formulated peptides, and the volume was increased to 0.15 ml using GVBS++ buffer and 0.5 ml RBCs. The samples were spun at 3,000 rpm for 5 minutes, the supernatant was collected, and read at 412 nm. Values ​​are expressed as a percentage of the positive control consisting of human O serum and AB erythrocytes in GVBS++ buffer without peptide addition. PA-dPEG24 and PA-I8Sar formulated in citrate, ascorbic acid, and methionine excipients were able to maintain dose-dependent inhibition of complement activation in the hemolysis assay compared to the original histidine-formulated molecule (Figures 3A-3B). Under these experimental conditions, PA-dPEG24 formulated in ascorbic acid, citrate, or histidine showed slightly increased complement inhibitory activity compared to the peptide formulated in methionine (Figure 3A). In the case of PA-I8Sar, formulations containing each of the four excipients showed similar levels of activity (Figure 3B). These findings demonstrate that PA-dPEG24 and PA-I8Sar can be efficiently solubilized in four different excipients that maintain the functional activity of these peptides.

[0100] Example 4: Preparation of a stable liquid formulation of RLS-0088 material (Table 2) Composition table The quantity needs to be corrected depending on the purity and moisture content of TIFF2023549126000010.tif92139*RLS-0088. (Table 3) Combination table TIFF2023549126000011.tif94145* Amount of RLS-0088 = Pure RLS-0088 / (Purity %) / (100% - Moisture Content %) = 0.2g / (95.5%) / (100% - 2.9%) = 0.216g.

[0101] Protocol Preparation of vehicle (F32V) for formulation F32V vehicles were prepared in 50 mL Falcon tubes according to Table 4 below. The tubes were vortexed to dissolve all solids.

[0102] (Table 4) F32V Vehicle TIFF2023549126000012.tif57132

[0103] Preparation of formulation (F32) RLS-0088 was weighed and transferred to a 15 mL Falcon tube for F32. QS for batch sizes using the corresponding vehicle was prepared according to Table 5 below.

[0104] (Table 5) TIFF2023549126000013.tif46130

[0105] Each tube was vortexed to dissolve the solid. Each sample was adjusted to the target pH using NaOH or HCl solution. The solution was filtered through a 0.2 μm nylon filter. The filtrate was transferred to two HPLC vials, one kept in a 25°C chamber and the other in a 2–8°C chamber. The filtrate was assayed at T0 and 24 hours. At 24 hours, the particle size of the filtrate was checked using an Accusizer. For the remaining formulations, 0.8 mL / vial of the formulation was transferred to four 2 mL lipid-digesting glass vials. The vials were frozen at -20°C. After freezing, two of these vials were lyophilized. The frozen and lyophilized vials were thawed, reconstituted, and kept at 2–8°C or 25°C. The samples were tested according to Table 6.

[0106] (Table 6) Test Protocol Tested by TIFF2023549126000014.tif85158*Accusizer

[0107] HPLC samples were prepared by transferring 100 mg of each sample to a 10 mL volumetric flask. The samples were then quick-sampled to 5 mL with a diluent.

[0108] result Figure 4 shows vials of formulations containing RLS-0088 under different storage conditions. Table 7 below shows the results for Accusizer. (Table 7) Accusizer results TIFF2023549126000015.tif147159*1400mg / 70kg human-based; 1400mg / (40mg / mL)=35mL. Note: F: freeze-thaw; L: freeze-dry

[0109] All F32 samples, regardless of whether they were freeze-thawed or lyophilized-reconstituted, were stored at 25°C for 24 hours and at 2–8°C for 48 hours, and then tested for USP26. <788> It met, or came very close to, the criteria for acceptable particulate matter.

[0110] HPLC results Sample preparation was carried out according to Table 8. (Table 8) HPLC samples TIFF2023549126000016.tif63163 The target concentration is calculated using the theoretical assay formula assuming all solids are dissolved: API weight * purity * (100% - water content) / (vehicle weight + API weight).

[0111] The stability results are shown in Table 9 below. (Table 9) Stability results TIFF2023549126000017.tif145158 Note: F: Freeze-thaw; L: Freeze-drying

[0112] The F32 formulation was stable for at least 24 hours at 25°C and at at least 48 hours at 2–8°C. All lyophilized-reconstituted and freeze-thawed F32 formulations were stable for 24 hours at 25°C and at 48 hours at 2–8°C.

[0113] Molar osmotic concentration (Table 10) Molar osmotic concentration TIFF2023549126000018.tif44159

[0114] The molar osmotic pressure of the undiluted F32 formulation could not be measured with an osmometer. Therefore, for measurement, the sample was diluted 1:1 v / v with DI water. The molar osmotic pressure of F32 was 411 mOsm, which is acceptable for IV injection / infusion.

[0115] conclusion The F32 formulation was stable at 25°C for at least 24 hours and at 2–8°C for at least 48 hours. All lyophilized-reconstituted and freeze-thawed F32 formulations were stable at 25°C for 24 hours and at 2–8°C for 48 hours. All F32 samples, regardless of whether they were freeze-thawed or lyophilized-reconstituted, were stable after being stored at 25°C for 24 hours and at 2–8°C for 48 hours, and then tested positive for USP26. <788> It met the criteria for acceptable particulate matter. The molar osmotic concentration of F32 is 411 mOsm, which is acceptable for IV injection / infusion.

[0116] Example 5: Preparation of stable liquid and lyophilized pediatric formulations for RLS-0071 The objectives of this embodiment were to (i) prepare formulations F7, F8, F9, and F10; (ii) lyophilize the formulations in vials using an existing lyophilization cycle; and (iii) prepare stable liquid and lyophilized formulations of RLS-0071 for pediatric use by reconstituting the lyophilized product, thawing the frozen vials, and performing test assays for impurities and particulate matter.

[0117] material Tables 11 and 12 show the compositions of various formulations. (Table 11) Composition table TIFF2023549126000019.tif99161 (Table 12) Combination table TIFF2023549126000020.tif101162

[0118] Protocol The formulations (F7-F10) were prepared as follows: 400 mg of RLS-0071 was weighed and transferred to Falcon tubes for F7-F10. Methionine, EDTA.Na2, trehalose, and sucrose were weighed and transferred to the corresponding Falcon tubes. The formulations were brought to 40 g using WFI or buffer. Each vial was vortexed to dissolve the solids. Each sample was adjusted to the target pH value using NaOH or HCl solution.

[0119] Next, the formulations were lyophilized as follows: F7–F10 were filtered through a 0.2 μm filter. 4 mL of each filtrate was divided equally into 10 mL clean lipid-digesting glass vials. The glass vials were lyophilized using an existing lyophilization cycle. The lyophilized vials were then reconstituted, and the reconstituted and thawed solutions were stored at 2–8°C for 12–24 hours and at 25°C for 2 hours. The solutions were then assayed for particulate matter and impurities.

[0120] result Figure 5 shows vials of formulations containing RLS-0071 under different storage conditions. Tables 13 and 14 below show the HPLC and particulate matter results.

[0121] (Table 13) HPLC results TIFF2023549126000021.tif142170

[0122] (Table 14) Particulate matter TIFF2023549126000022.tif58161*Note: The preparation was diluted 20 times with DI water (1:20, v / v).

[0123] conclusion During the preparation of the formulation, a turbid precipitate was observed in F9. After filtration, assay testing indicated that the precipitate was the active ingredient (API). Particulate matter testing results for F7, F8, and F10 showed that using water to construct the solution was superior to using buffer. Lyophilization results showed that F8, containing EDTA-Na2 and methionine, did not show significant changes compared to F7. F7 was shown to be a superior lead formulation when the formulation was lyophilized. F8 was shown to be a superior lead formulation when the formulation was aqueous.

[0124] Example 6: Administration of pharmaceutical preparations To treat or prevent a disease or condition, a pharmaceutical formulation containing a therapeutically effective amount of a lipid-based preparation of SEQ ID NO:3 is administered to the subject in need. Administration may be via any appropriate route (e.g., injection, infusion, implantation).

[0125] To modulate the complement system in the target population, a pharmaceutical formulation containing a therapeutically effective amount of a lipid-based preparation of SEQ ID NO:3 is administered to the target population in need. Administration may be via any appropriate route (e.g., injection, infusion, implantation).

[0126] To treat or prevent a disease or condition, a pharmaceutical formulation containing a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3, combined with an excipient suitable for intravenous administration, is administered intravenously to the subject in need. The excipient can be selected based on the subject's age.

[0127] To modulate the complement system in the target population, a pharmaceutical formulation containing a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3, combined with an excipient suitable for intravenous administration, is administered intravenously to the target population in need. The excipient can be selected based on the target population's age.

[0128] List of types The following is a non-exclusive list of embodiments provided herein. 1. A composition comprising a therapeutically effective amount of SEQ ID NO:3 and a lipid-based carrier. 2. The composition according to embodiment 1, wherein the lipid-based carrier comprises lipid micelles. 3. The composition according to embodiment 1 or 2, wherein the lipid-based carrier comprises a lipid emulsion. 4. The composition according to embodiment 3, wherein the lipid-based carrier is present in an amount of about 10% w / v to about 20% w / v. 5. A composition comprising a therapeutically effective amount of SEQ ID NO:2 or SEQ ID NO:3 and at least one excipient. 6. The composition according to embodiment 5, wherein at least one of the excipients is suitable for intravenous administration. 7. The composition according to embodiment 5 or 6, wherein the at least one excipient is selected from the group consisting of citric acid, ascorbic acid, amino acids, and combinations thereof. 8. The composition according to embodiment 7, wherein the citric acid contains sodium citrate. 9. The composition according to embodiment 8, wherein the citric acid is present in an amount of about 1% w / v to about 5% w / v. 10. The composition according to embodiment 7, wherein the ascorbic acid comprises sodium ascorbate. 11. The composition according to embodiment 10, wherein the ascorbic acid is present in an amount of about 1% w / v to about 5% w / v. 12. The composition according to embodiment 7, wherein the aforementioned amino acid is L-methionine. 13. The composition according to embodiment 12, wherein the aforementioned amino acid is present in an amount of approximately 0.01% w / v to approximately 5% w / v. 14. A composition according to any of embodiments 1 to 13, wherein SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of approximately 0.001 to approximately 200 milligrams (mg / kg) per kilogram of body weight. 15. A composition according to any of embodiments 1 to 14, wherein SEQ ID NO:2 and / or SEQ ID NO:3 are present in an amount of approximately 5 to approximately 160 mg / kg. 16. A composition according to any of embodiments 1 to 13, wherein SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of approximately 1 mg / ml to approximately 100 mg / ml. 17. A composition according to any of embodiments 1 to 13, wherein SEQ ID NO:2 or SEQ ID NO:3 is present in an amount of approximately 10 mg / ml to approximately 80 mg / ml. 18. A method for altering cytokine expression, comprising the step of administering one of the compositions of embodiments 1 to 17 to a subject in need of such alteration. 19. The method according to embodiment 18, wherein the administration includes parenteral administration. 20. The method according to embodiment 18 or 19, wherein the administration includes intravenous administration. twenty one. A method for treating or preventing a disease or condition, comprising the step of administering one of the compositions of embodiments 1 to 17 to a subject in need of such treatment or prevention. twenty two. The method according to embodiment 21, wherein the administration includes parenteral administration. twenty three. The method according to embodiment 21 or 22, wherein the administration includes intravenous administration.

[0129] Table of arrays TIFF2023549126000023.tif51161

[0130] While several possible embodiments are disclosed above, the embodiments of the present invention are not limited in this way. These exemplary embodiments are not intended to be exhaustive or to unnecessarily limit the scope of the invention, but rather have been selected and described to illustrate the principles of the invention so that others skilled in the art can carry it out. Indeed, it is expected that various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

[0131] References TIFF2023549126000024.tif203158TIFF2023549126000025.tif34157

Claims

1. A composition comprising a therapeutically effective amount of SEQ ID NO:2 and at least one excipient.

2. 10. The composition of claim 1, wherein the at least one excipient is suitable for intravenous administration.

3. 3. The composition of claim 1 or 2, wherein the at least one excipient is selected from the group consisting of citric acid, ascorbic acid, amino acids, and combinations thereof.

4. 4. The composition of claim 3, wherein the citric acid comprises sodium citrate, and optionally the citric acid is present in an amount of about 1% w / v to about 5% w / v.

5. 4. The composition of claim 3, wherein the ascorbic acid comprises sodium ascorbate, and optionally the ascorbic acid is present in an amount of about 1% w / v to about 5% w / v.

6. 4. The composition of claim 3, wherein the amino acid comprises L-methionine, and optionally, the amino acid is present in an amount of about 0.01% w / v to about 5% w / v.

7. SEQ ID NO:2 is present in an amount of about 0.001 to about 200 milligrams per kilogram of body weight (mg / kg); and / or SEQ ID NO:2 is present in an amount of about 5 to about 160 mg / kg; The composition according to any one of claims 1 to 6.

8. SEQ ID NO:2 is present in an amount of about 1 mg / ml to about 100 mg / ml; or SEQ ID NO:2 is present in an amount of about 10 mg / ml to about 80 mg / ml; The composition according to any one of claims 1 to 6.

9. 10. The composition of any one of claims 1 to 8, for use in a method of altering cytokine expression, said method comprising administering said composition to a subject in need thereof.

10. 10. The composition of any one of claims 1 to 8 for use in a method of treating or preventing a disease or condition, said method comprising the step of administering said composition to a subject in need thereof.

11. and / or said administration comprises parenteral administration; wherein the administering comprises intravenous administration; 11. The composition of claim 9 or 10.

12. A composition described in any one of claims 1 to 11 formulated for delivery by routes such as oral, topical, mucosal, sublingual, nasal, naso / oro (naso / oro) gastric gavage and intratracheal administration.

13. In the form of a liquid, foam, cream, spray, powder, or gel; or in the form of a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, or syrup; The composition according to any one of claims 1 to 11.

14. The composition of claim 13, wherein the solution or suspension contains ethylenediaminetetraacetic acid (EDTA).

15. A composition according to any one of claims 1 to 11, comprising trehalose.